PITTSBURGH — Mylan N.V. has launched methylphenidate hydrochloride extended-release tablets, a medication for attention deficit hyperactivity disorder (ADHD), in the United States.
Mylan said its product, a generic version of Concerta tablets from Janssen Pharmaceuticals Inc., comes in dosages of 18 mg, 27 mg, 36 mg and 54 mg.
“The launch of generic Concerta tablets demonstrates Mylan’s leadership in complex development and manufacturing and in bringing to market a broad portfolio of high-quality generics,” stated Mylan chief executive officer Heather Bresch. “This launch also further strengthens our robust portfolio of central nervous system medications, which is the largest in the U.S. with more than 100 products. We’re excited about bringing another generic in this therapeutic area to market and expanding access to help patients.”
Methylphenidate hydrochloride ER tablets (18 mg, 27 mg, 36 mg and 54 mg) totaled U.S. sales of approximately $1.59 billion for the 12 months ended Oct. 31, according to IMS Health data reported by Mylan.